Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct 9:7:87.
doi: 10.1186/1477-7525-7-87.

Do neurooncological patients and their significant others agree on quality of life ratings?

Johannes M Giesinger  1 , Miriam Golser, Astrid Erharter, Georg Kemmler, Gabriele Schauer-Maurer, Guenter Stockhammer, Armin Muigg, Markus Hutterer, Gerhard Rumpold, Bernhard Holzner
Affiliations

Do neurooncological patients and their significant others agree on quality of life ratings?

Johannes M Giesinger et al. Health Qual Life Outcomes. .

Abstract

Introduction: Patients suffering from brain tumours often experience a wide range of cognitive impairments that impair their ability to report on their quality of life and symptom burden. The use of proxy ratings by significant others may be a promising alternative to gain information for medical decision making or research purposes, if self-ratings are not obtainable. Our study investigated the agreement of quality of life and symptom ratings by the patient him/herself or by a significant other.

Methods: Patients with primary brain tumours were recruited at the neurooncological outpatient unit of Innsbruck Medical University. Quality of life self- and proxy-ratings were collected using the EORTC QLQ-C30 and its brain cancer module, the QLQ-BN20.

Results: Between May 2005 and August 2007, 42 pairs consisting of a patient and his/her significant other were included in the study. Most of the employed quality of life scales showed fairly good agreement between patient- and proxy-ratings (median correlation 0.46). This was especially true for Physical Functioning, Sleeping Disturbances, Appetite Loss, Constipation, Taste Alterations, Visual Disorders, Motor Dysfunction, Communication Deficits, Hair Loss, Itchy Skin, Motor Dysfunction and Hair Loss. Worse rater agreement was found for Social Functioning, Emotional Functioning, Cognitive Functioning, Fatigue, Pain, Dyspnoea and Seizures.

Conclusion: The assessment of quality of life in brain cancer patients through ratings from their significant others seems to be a feasible strategy to gain information about certain aspects of patient's quality of life and symptom burden, if the patient is not able to provide information himself.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean Differences (Patients minus Proxy) for the QLQ-C30 (dashed reference lines indicate margin for a relevant difference).
Figure 2
Figure 2
Bland and Altman plots for Physical Functioning (2a), Social Functioning (2b), Motor Dysfunction (2c) and Seizures (2d).
Figure 3
Figure 3
Mean Differences (Patients minus Proxy) for the QLQ-BN20 (dashed reference lines indicate margin for a relevant difference).
See this image and copyright information in PMC

References

    1. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22:714–24. doi: 10.1200/JCO.2004.06.078. - DOI - PubMed
    1. Taenzer P, Bultz BD, Carlson LE, Speca M, DeGagne T, Olson K, Doll R, Rosberger Z. Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology. 2000;9:203–13. doi: 10.1002/1099-1611(200005/06)9:3<203::AID-PON453>3.3.CO;2-P. - DOI - PubMed
    1. MacDonald D, Kiebert G, Padros M, Yung A, Olson J. Benefit of temozolamide compared to procarbazine treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Invest. 2005;23:138–144. doi: 10.1081/CNV-200050453. - DOI - PubMed
    1. Prados M, Schold S, Fine H, Jaeckle K, Hochberg F, Mechtler L, Fetell M, Phuphanich S, Feun L, Janus T, Ford K, Graney W. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-Oncol. 2003;5:96–103. doi: 10.1215/15228517-5-2-96. - DOI - PMC - PubMed
    1. Hart M, Grant R, Garside R, Rogers G, Somerville M, Stein K. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2008;4:CD007415. - PubMed

Publication types